Small Molecule Inhibitors of LcrF, a Yersinia pseudotuberculosis Transcription Factor, Attenuate Virulence and Limit Infection in a Murine Pneumonia Model

LcrF (VirF), a transcription factor in the multiple adaptational response (MAR) family, regulates expression of the Yersinia type III secretion system (T3SS). Yersinia pseudotuberculosis lcrF-null mutants showed attenuated virulence in tissue culture and animal models of infection. Targeting of LcrF...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Infection and Immunity 2010-11, Vol.78 (11), p.4683-4690
Hauptverfasser: Garrity-Ryan, Lynne K, Kim, Oak K, Balada-Llasat, Joan-Miquel, Bartlett, Victoria J, Verma, Atul K, Fisher, Michael L, Castillo, Cynthia, Songsungthong, Warangkhana, Tanaka, S. Ken, Levy, Stuart B, Mecsas, Joan, Alekshun, Michael N
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4690
container_issue 11
container_start_page 4683
container_title Infection and Immunity
container_volume 78
creator Garrity-Ryan, Lynne K
Kim, Oak K
Balada-Llasat, Joan-Miquel
Bartlett, Victoria J
Verma, Atul K
Fisher, Michael L
Castillo, Cynthia
Songsungthong, Warangkhana
Tanaka, S. Ken
Levy, Stuart B
Mecsas, Joan
Alekshun, Michael N
description LcrF (VirF), a transcription factor in the multiple adaptational response (MAR) family, regulates expression of the Yersinia type III secretion system (T3SS). Yersinia pseudotuberculosis lcrF-null mutants showed attenuated virulence in tissue culture and animal models of infection. Targeting of LcrF offers a novel, antivirulence strategy for preventing Yersinia infection. A small molecule library was screened for inhibition of LcrF-DNA binding in an in vitro assay. All of the compounds lacked intrinsic antibacterial activity and did not demonstrate toxicity against mammalian cells. A subset of these compounds inhibited T3SS-dependent cytotoxicity of Y. pseudotuberculosis toward macrophages in vitro. In a murine model of Y. pseudotuberculosis pneumonia, two compounds significantly reduced the bacterial burden in the lungs and afforded a dramatic survival advantage. The MAR family of transcription factors is well conserved, with members playing central roles in pathogenesis across bacterial genera; thus, the inhibitors could have broad applicability.
doi_str_mv 10.1128/IAI.01305-09
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_20823209</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>815539873</sourcerecordid><originalsourceid>FETCH-LOGICAL-c496t-ef76b6c1e30ee30cbd24a03c1806b6c982e1dfb904e358249b76f4647061a5593</originalsourceid><addsrcrecordid>eNqFkV-LEzEUxQdR3Lr65rMGQXzprPk3meRFKIvVQovC7go-hUx6p43MJDWZUfwqfloz27rqkw8hJPnlnHvvKYqnBF8QQuXr1WJ1gQnDVYnVvWJGsJJlVVF6v5hhTFSpKlGfFY9S-pKPnHP5sDijWFJGsZoVP69603VoEzqwYwdo5feucUOICYUWrW1czpFBnyEm551BhwTjNgxjAzHjIbmErqPxyUZ3GFzwaGls_jxHi2EAP5oB0CcXs7C3gIzforXr3ZBdWrC3vPNZfjNG5wF99DD2YbLZhC10j4sHrekSPDnt58XN8u315fty_eHd6nKxLi1XYiihrUUjLAGGIS_bbCk3mFki8XSvJAWybRuFObBKUq6aWrRc8BoLYqpKsfPizVH3MDY9bC34IZpOH6LrTfyhg3H63xfv9noXvmmqasGYyAKvTgIxfB0hDbp3yULXGQ9hTFqSqmJK1uy_ZJ3LoZxyksn5kbQxpBShvauHYD3lrnPu-jZ3jacenv3dwx38O-gMvDwBJlnTtTk069IfjrE8EDZxL47c3u32310EbVKvXZ5BLbOv5kJObTw_Qq0J2uxiFrq5olMxRGEiKGW_AFYwzF0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>759324241</pqid></control><display><type>article</type><title>Small Molecule Inhibitors of LcrF, a Yersinia pseudotuberculosis Transcription Factor, Attenuate Virulence and Limit Infection in a Murine Pneumonia Model</title><source>American Society for Microbiology</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Garrity-Ryan, Lynne K ; Kim, Oak K ; Balada-Llasat, Joan-Miquel ; Bartlett, Victoria J ; Verma, Atul K ; Fisher, Michael L ; Castillo, Cynthia ; Songsungthong, Warangkhana ; Tanaka, S. Ken ; Levy, Stuart B ; Mecsas, Joan ; Alekshun, Michael N</creator><creatorcontrib>Garrity-Ryan, Lynne K ; Kim, Oak K ; Balada-Llasat, Joan-Miquel ; Bartlett, Victoria J ; Verma, Atul K ; Fisher, Michael L ; Castillo, Cynthia ; Songsungthong, Warangkhana ; Tanaka, S. Ken ; Levy, Stuart B ; Mecsas, Joan ; Alekshun, Michael N</creatorcontrib><description>LcrF (VirF), a transcription factor in the multiple adaptational response (MAR) family, regulates expression of the Yersinia type III secretion system (T3SS). Yersinia pseudotuberculosis lcrF-null mutants showed attenuated virulence in tissue culture and animal models of infection. Targeting of LcrF offers a novel, antivirulence strategy for preventing Yersinia infection. A small molecule library was screened for inhibition of LcrF-DNA binding in an in vitro assay. All of the compounds lacked intrinsic antibacterial activity and did not demonstrate toxicity against mammalian cells. A subset of these compounds inhibited T3SS-dependent cytotoxicity of Y. pseudotuberculosis toward macrophages in vitro. In a murine model of Y. pseudotuberculosis pneumonia, two compounds significantly reduced the bacterial burden in the lungs and afforded a dramatic survival advantage. The MAR family of transcription factors is well conserved, with members playing central roles in pathogenesis across bacterial genera; thus, the inhibitors could have broad applicability.</description><identifier>ISSN: 0019-9567</identifier><identifier>EISSN: 1098-5522</identifier><identifier>DOI: 10.1128/IAI.01305-09</identifier><identifier>PMID: 20823209</identifier><identifier>CODEN: INFIBR</identifier><language>eng</language><publisher>Washington, DC: American Society for Microbiology</publisher><subject>Animals ; Anti-Bacterial Agents - administration &amp; dosage ; Anti-Bacterial Agents - chemical synthesis ; Anti-Bacterial Agents - chemistry ; Anti-Bacterial Agents - pharmacology ; Bacterial Proteins - antagonists &amp; inhibitors ; Bacterial Proteins - metabolism ; Bacteriology ; Benzimidazoles - administration &amp; dosage ; Benzimidazoles - chemical synthesis ; Benzimidazoles - chemistry ; Benzimidazoles - pharmacology ; Biological and medical sciences ; Cell Line ; Disease Models, Animal ; Female ; Fundamental and applied biological sciences. Psychology ; Humans ; Lung - microbiology ; Macrophages - microbiology ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Microbiology ; Miscellaneous ; Molecular Pathogenesis ; Pneumonia, Bacterial - drug therapy ; Pneumonia, Bacterial - microbiology ; Pneumonia, Bacterial - mortality ; Pneumonia, Bacterial - pathology ; Transcription Factors - antagonists &amp; inhibitors ; Transcription Factors - metabolism ; Treatment Outcome ; Virulence ; Yersinia pseudotuberculosis ; Yersinia pseudotuberculosis - drug effects ; Yersinia pseudotuberculosis - metabolism ; Yersinia pseudotuberculosis - pathogenicity ; Yersinia pseudotuberculosis Infections - drug therapy ; Yersinia pseudotuberculosis Infections - microbiology ; Yersinia pseudotuberculosis Infections - mortality ; Yersinia pseudotuberculosis Infections - pathology</subject><ispartof>Infection and Immunity, 2010-11, Vol.78 (11), p.4683-4690</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright © 2010, American Society for Microbiology 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c496t-ef76b6c1e30ee30cbd24a03c1806b6c982e1dfb904e358249b76f4647061a5593</citedby><cites>FETCH-LOGICAL-c496t-ef76b6c1e30ee30cbd24a03c1806b6c982e1dfb904e358249b76f4647061a5593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2976336/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2976336/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,729,782,786,887,3190,3191,27931,27932,53798,53800</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=23347039$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20823209$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garrity-Ryan, Lynne K</creatorcontrib><creatorcontrib>Kim, Oak K</creatorcontrib><creatorcontrib>Balada-Llasat, Joan-Miquel</creatorcontrib><creatorcontrib>Bartlett, Victoria J</creatorcontrib><creatorcontrib>Verma, Atul K</creatorcontrib><creatorcontrib>Fisher, Michael L</creatorcontrib><creatorcontrib>Castillo, Cynthia</creatorcontrib><creatorcontrib>Songsungthong, Warangkhana</creatorcontrib><creatorcontrib>Tanaka, S. Ken</creatorcontrib><creatorcontrib>Levy, Stuart B</creatorcontrib><creatorcontrib>Mecsas, Joan</creatorcontrib><creatorcontrib>Alekshun, Michael N</creatorcontrib><title>Small Molecule Inhibitors of LcrF, a Yersinia pseudotuberculosis Transcription Factor, Attenuate Virulence and Limit Infection in a Murine Pneumonia Model</title><title>Infection and Immunity</title><addtitle>Infect Immun</addtitle><description>LcrF (VirF), a transcription factor in the multiple adaptational response (MAR) family, regulates expression of the Yersinia type III secretion system (T3SS). Yersinia pseudotuberculosis lcrF-null mutants showed attenuated virulence in tissue culture and animal models of infection. Targeting of LcrF offers a novel, antivirulence strategy for preventing Yersinia infection. A small molecule library was screened for inhibition of LcrF-DNA binding in an in vitro assay. All of the compounds lacked intrinsic antibacterial activity and did not demonstrate toxicity against mammalian cells. A subset of these compounds inhibited T3SS-dependent cytotoxicity of Y. pseudotuberculosis toward macrophages in vitro. In a murine model of Y. pseudotuberculosis pneumonia, two compounds significantly reduced the bacterial burden in the lungs and afforded a dramatic survival advantage. The MAR family of transcription factors is well conserved, with members playing central roles in pathogenesis across bacterial genera; thus, the inhibitors could have broad applicability.</description><subject>Animals</subject><subject>Anti-Bacterial Agents - administration &amp; dosage</subject><subject>Anti-Bacterial Agents - chemical synthesis</subject><subject>Anti-Bacterial Agents - chemistry</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Bacterial Proteins - antagonists &amp; inhibitors</subject><subject>Bacterial Proteins - metabolism</subject><subject>Bacteriology</subject><subject>Benzimidazoles - administration &amp; dosage</subject><subject>Benzimidazoles - chemical synthesis</subject><subject>Benzimidazoles - chemistry</subject><subject>Benzimidazoles - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cell Line</subject><subject>Disease Models, Animal</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Humans</subject><subject>Lung - microbiology</subject><subject>Macrophages - microbiology</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Inbred C57BL</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Molecular Pathogenesis</subject><subject>Pneumonia, Bacterial - drug therapy</subject><subject>Pneumonia, Bacterial - microbiology</subject><subject>Pneumonia, Bacterial - mortality</subject><subject>Pneumonia, Bacterial - pathology</subject><subject>Transcription Factors - antagonists &amp; inhibitors</subject><subject>Transcription Factors - metabolism</subject><subject>Treatment Outcome</subject><subject>Virulence</subject><subject>Yersinia pseudotuberculosis</subject><subject>Yersinia pseudotuberculosis - drug effects</subject><subject>Yersinia pseudotuberculosis - metabolism</subject><subject>Yersinia pseudotuberculosis - pathogenicity</subject><subject>Yersinia pseudotuberculosis Infections - drug therapy</subject><subject>Yersinia pseudotuberculosis Infections - microbiology</subject><subject>Yersinia pseudotuberculosis Infections - mortality</subject><subject>Yersinia pseudotuberculosis Infections - pathology</subject><issn>0019-9567</issn><issn>1098-5522</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkV-LEzEUxQdR3Lr65rMGQXzprPk3meRFKIvVQovC7go-hUx6p43MJDWZUfwqfloz27rqkw8hJPnlnHvvKYqnBF8QQuXr1WJ1gQnDVYnVvWJGsJJlVVF6v5hhTFSpKlGfFY9S-pKPnHP5sDijWFJGsZoVP69603VoEzqwYwdo5feucUOICYUWrW1czpFBnyEm551BhwTjNgxjAzHjIbmErqPxyUZ3GFzwaGls_jxHi2EAP5oB0CcXs7C3gIzforXr3ZBdWrC3vPNZfjNG5wF99DD2YbLZhC10j4sHrekSPDnt58XN8u315fty_eHd6nKxLi1XYiihrUUjLAGGIS_bbCk3mFki8XSvJAWybRuFObBKUq6aWrRc8BoLYqpKsfPizVH3MDY9bC34IZpOH6LrTfyhg3H63xfv9noXvmmqasGYyAKvTgIxfB0hDbp3yULXGQ9hTFqSqmJK1uy_ZJ3LoZxyksn5kbQxpBShvauHYD3lrnPu-jZ3jacenv3dwx38O-gMvDwBJlnTtTk069IfjrE8EDZxL47c3u32310EbVKvXZ5BLbOv5kJObTw_Qq0J2uxiFrq5olMxRGEiKGW_AFYwzF0</recordid><startdate>20101101</startdate><enddate>20101101</enddate><creator>Garrity-Ryan, Lynne K</creator><creator>Kim, Oak K</creator><creator>Balada-Llasat, Joan-Miquel</creator><creator>Bartlett, Victoria J</creator><creator>Verma, Atul K</creator><creator>Fisher, Michael L</creator><creator>Castillo, Cynthia</creator><creator>Songsungthong, Warangkhana</creator><creator>Tanaka, S. Ken</creator><creator>Levy, Stuart B</creator><creator>Mecsas, Joan</creator><creator>Alekshun, Michael N</creator><general>American Society for Microbiology</general><general>American Society for Microbiology (ASM)</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QL</scope><scope>7T5</scope><scope>7TM</scope><scope>C1K</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20101101</creationdate><title>Small Molecule Inhibitors of LcrF, a Yersinia pseudotuberculosis Transcription Factor, Attenuate Virulence and Limit Infection in a Murine Pneumonia Model</title><author>Garrity-Ryan, Lynne K ; Kim, Oak K ; Balada-Llasat, Joan-Miquel ; Bartlett, Victoria J ; Verma, Atul K ; Fisher, Michael L ; Castillo, Cynthia ; Songsungthong, Warangkhana ; Tanaka, S. Ken ; Levy, Stuart B ; Mecsas, Joan ; Alekshun, Michael N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c496t-ef76b6c1e30ee30cbd24a03c1806b6c982e1dfb904e358249b76f4647061a5593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - administration &amp; dosage</topic><topic>Anti-Bacterial Agents - chemical synthesis</topic><topic>Anti-Bacterial Agents - chemistry</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Bacterial Proteins - antagonists &amp; inhibitors</topic><topic>Bacterial Proteins - metabolism</topic><topic>Bacteriology</topic><topic>Benzimidazoles - administration &amp; dosage</topic><topic>Benzimidazoles - chemical synthesis</topic><topic>Benzimidazoles - chemistry</topic><topic>Benzimidazoles - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cell Line</topic><topic>Disease Models, Animal</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Humans</topic><topic>Lung - microbiology</topic><topic>Macrophages - microbiology</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Inbred C57BL</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Molecular Pathogenesis</topic><topic>Pneumonia, Bacterial - drug therapy</topic><topic>Pneumonia, Bacterial - microbiology</topic><topic>Pneumonia, Bacterial - mortality</topic><topic>Pneumonia, Bacterial - pathology</topic><topic>Transcription Factors - antagonists &amp; inhibitors</topic><topic>Transcription Factors - metabolism</topic><topic>Treatment Outcome</topic><topic>Virulence</topic><topic>Yersinia pseudotuberculosis</topic><topic>Yersinia pseudotuberculosis - drug effects</topic><topic>Yersinia pseudotuberculosis - metabolism</topic><topic>Yersinia pseudotuberculosis - pathogenicity</topic><topic>Yersinia pseudotuberculosis Infections - drug therapy</topic><topic>Yersinia pseudotuberculosis Infections - microbiology</topic><topic>Yersinia pseudotuberculosis Infections - mortality</topic><topic>Yersinia pseudotuberculosis Infections - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garrity-Ryan, Lynne K</creatorcontrib><creatorcontrib>Kim, Oak K</creatorcontrib><creatorcontrib>Balada-Llasat, Joan-Miquel</creatorcontrib><creatorcontrib>Bartlett, Victoria J</creatorcontrib><creatorcontrib>Verma, Atul K</creatorcontrib><creatorcontrib>Fisher, Michael L</creatorcontrib><creatorcontrib>Castillo, Cynthia</creatorcontrib><creatorcontrib>Songsungthong, Warangkhana</creatorcontrib><creatorcontrib>Tanaka, S. Ken</creatorcontrib><creatorcontrib>Levy, Stuart B</creatorcontrib><creatorcontrib>Mecsas, Joan</creatorcontrib><creatorcontrib>Alekshun, Michael N</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Infection and Immunity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garrity-Ryan, Lynne K</au><au>Kim, Oak K</au><au>Balada-Llasat, Joan-Miquel</au><au>Bartlett, Victoria J</au><au>Verma, Atul K</au><au>Fisher, Michael L</au><au>Castillo, Cynthia</au><au>Songsungthong, Warangkhana</au><au>Tanaka, S. Ken</au><au>Levy, Stuart B</au><au>Mecsas, Joan</au><au>Alekshun, Michael N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Small Molecule Inhibitors of LcrF, a Yersinia pseudotuberculosis Transcription Factor, Attenuate Virulence and Limit Infection in a Murine Pneumonia Model</atitle><jtitle>Infection and Immunity</jtitle><addtitle>Infect Immun</addtitle><date>2010-11-01</date><risdate>2010</risdate><volume>78</volume><issue>11</issue><spage>4683</spage><epage>4690</epage><pages>4683-4690</pages><issn>0019-9567</issn><eissn>1098-5522</eissn><coden>INFIBR</coden><abstract>LcrF (VirF), a transcription factor in the multiple adaptational response (MAR) family, regulates expression of the Yersinia type III secretion system (T3SS). Yersinia pseudotuberculosis lcrF-null mutants showed attenuated virulence in tissue culture and animal models of infection. Targeting of LcrF offers a novel, antivirulence strategy for preventing Yersinia infection. A small molecule library was screened for inhibition of LcrF-DNA binding in an in vitro assay. All of the compounds lacked intrinsic antibacterial activity and did not demonstrate toxicity against mammalian cells. A subset of these compounds inhibited T3SS-dependent cytotoxicity of Y. pseudotuberculosis toward macrophages in vitro. In a murine model of Y. pseudotuberculosis pneumonia, two compounds significantly reduced the bacterial burden in the lungs and afforded a dramatic survival advantage. The MAR family of transcription factors is well conserved, with members playing central roles in pathogenesis across bacterial genera; thus, the inhibitors could have broad applicability.</abstract><cop>Washington, DC</cop><pub>American Society for Microbiology</pub><pmid>20823209</pmid><doi>10.1128/IAI.01305-09</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0019-9567
ispartof Infection and Immunity, 2010-11, Vol.78 (11), p.4683-4690
issn 0019-9567
1098-5522
language eng
recordid cdi_pubmed_primary_20823209
source American Society for Microbiology; MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Animals
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - chemical synthesis
Anti-Bacterial Agents - chemistry
Anti-Bacterial Agents - pharmacology
Bacterial Proteins - antagonists & inhibitors
Bacterial Proteins - metabolism
Bacteriology
Benzimidazoles - administration & dosage
Benzimidazoles - chemical synthesis
Benzimidazoles - chemistry
Benzimidazoles - pharmacology
Biological and medical sciences
Cell Line
Disease Models, Animal
Female
Fundamental and applied biological sciences. Psychology
Humans
Lung - microbiology
Macrophages - microbiology
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Microbiology
Miscellaneous
Molecular Pathogenesis
Pneumonia, Bacterial - drug therapy
Pneumonia, Bacterial - microbiology
Pneumonia, Bacterial - mortality
Pneumonia, Bacterial - pathology
Transcription Factors - antagonists & inhibitors
Transcription Factors - metabolism
Treatment Outcome
Virulence
Yersinia pseudotuberculosis
Yersinia pseudotuberculosis - drug effects
Yersinia pseudotuberculosis - metabolism
Yersinia pseudotuberculosis - pathogenicity
Yersinia pseudotuberculosis Infections - drug therapy
Yersinia pseudotuberculosis Infections - microbiology
Yersinia pseudotuberculosis Infections - mortality
Yersinia pseudotuberculosis Infections - pathology
title Small Molecule Inhibitors of LcrF, a Yersinia pseudotuberculosis Transcription Factor, Attenuate Virulence and Limit Infection in a Murine Pneumonia Model
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T15%3A30%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Small%20Molecule%20Inhibitors%20of%20LcrF,%20a%20Yersinia%20pseudotuberculosis%20Transcription%20Factor,%20Attenuate%20Virulence%20and%20Limit%20Infection%20in%20a%20Murine%20Pneumonia%20Model&rft.jtitle=Infection%20and%20Immunity&rft.au=Garrity-Ryan,%20Lynne%20K&rft.date=2010-11-01&rft.volume=78&rft.issue=11&rft.spage=4683&rft.epage=4690&rft.pages=4683-4690&rft.issn=0019-9567&rft.eissn=1098-5522&rft.coden=INFIBR&rft_id=info:doi/10.1128/IAI.01305-09&rft_dat=%3Cproquest_pubme%3E815539873%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=759324241&rft_id=info:pmid/20823209&rfr_iscdi=true